Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [2] - The company markets three main products in the United States: MACI, Epicel, and holds an exclusive license for NexoBrid [2] Product Details - MACI is an autologous cellularized scaffold product for repairing symptomatic, full-thickness cartilage defects of the knee in adults [2] - Epicel is a permanent skin replacement for treating patients with deep dermal or full-thickness burns covering 30% or more of total body surface area [2] - NexoBrid is a biological orphan product indicated for eschar removal in patients with deep partial-thickness and/or full-thickness thermal burns [2] Upcoming Events - Vericel Corporation will participate in a fireside chat at the Stephens Annual Investment Conference on November 20, 2025, at 11:00 a.m. ET [1]

Core Viewpoint - Vericel Corporation will report its third-quarter 2025 financial results on November 6, 2025, and will host a conference call to discuss these results and business highlights [1]. Company Overview - Vericel Corporation is a leader in advanced therapies for sports medicine and severe burn care markets, combining biological innovations with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3]. - The company markets three products in the United States: - MACI®: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3]. - Epicel®: A permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3]. - NexoBrid®: A biological orphan product for eschar removal in patients with deep partial-thickness and/or full-thickness thermal burns, for which Vericel holds exclusive North American rights [3].

香港特区施政报告：吸引更多药企落户香港，进行罕见病药、高端肿瘤药及先进疗法制品等临床试验和治疗。成立“AI效能提升组”统筹和指导各政府部门有效应用AI，並研究重组不合时宜的工作流程。 ...

Company Overview - Vericel Corporation is a leader in advanced therapies for the sports medicine and severe burn care markets, combining innovations in biology with medical technologies to create a differentiated portfolio of cell therapies and specialty biologics [3] Upcoming Financial Results - Vericel will report its second-quarter 2025 financial results on July 31, 2025, with a conference call and webcast scheduled for 8:30 a.m. ET [1] - The live webcast can be accessed through the Investor Relations section of the Vericel website, and a replay will be available until July 31, 2026 [2] Product Portfolio - Vericel markets three main products in the United States: - MACI: An autologous cellularized scaffold product for repairing full-thickness cartilage defects in the knee [3] - Epicel: A permanent skin replacement for treating deep dermal or full-thickness burns covering 30% or more of total body surface area [3] - NexoBrid: A biological orphan product for eschar removal in burn patients, for which Vericel holds exclusive North American rights [3]